Desq Long
Sign in

Company

Travere Therapeutics, Inc.

TVTX · CIK 0001438533

SEC FORM 4
$6,567,875.94

Travere Therapeutics, Inc. (TVTX)

Sale of 101,691 shares at $64.5866 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 17, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$441,795.34

Travere Therapeutics, Inc. (TVTX)

Sale of 6,802 shares at $64.9508 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 17, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$2,532,226.62

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 108,493 shares at $23.34 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code M

Traded Sep 17, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$185,516.80

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 8,282 shares at $22.40 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code M

Traded Sep 17, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$538,917.19

Travere Therapeutics, Inc. (TVTX)

Sale of 8,282 shares at $65.0709 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code S

Traded Sep 17, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$4,109,397.03

Travere Therapeutics, Inc. (TVTX)

Sale of 65,104 shares at $63.1205 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$3,037,247.20

Travere Therapeutics, Inc. (TVTX)

Sale of 47,746 shares at $63.6126 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$6,286.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 350 shares at $17.96 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code M

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$850,300.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 55,000 shares at $15.46 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code M

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,545,600.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 57,500 shares at $26.88 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code M

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$4,570,928.94

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 195,841 shares at $23.34 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code M

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$6,307,964.36

Travere Therapeutics, Inc. (TVTX)

Sale of 99,716 shares at $63.2593 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$6,117,289.26

Travere Therapeutics, Inc. (TVTX)

Sale of 96,125 shares at $63.6389 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$476,232.96

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 17,717 shares at $26.88 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code M

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$5,920,181.55

Travere Therapeutics, Inc. (TVTX)

Sale of 93,604 shares at $63.2471 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$5,035,906.37

Travere Therapeutics, Inc. (TVTX)

Sale of 79,113 shares at $63.6546 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,125,000.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 100,000 shares at $11.25 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code M

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$850,300.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 55,000 shares at $15.46 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code M

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$579,750.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 37,500 shares at $15.46 per share.

Reporting Person REED ELIZABETH E · Officer Title Chief Legal Officer and GC · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001283303-26-000010 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,359,971.11

Travere Therapeutics, Inc. (TVTX)

Sale of 21,926 shares at $62.0255 per share.

Reporting Person REED ELIZABETH E · Officer Title Chief Legal Officer and GC · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001283303-26-000010 · filed 2026-09-17 · View filing →

SEC FORM 4
$868,964.69

Travere Therapeutics, Inc. (TVTX)

Sale of 13,874 shares at $62.6326 per share.

Reporting Person REED ELIZABETH E · Officer Title Chief Legal Officer and GC · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001283303-26-000010 · filed 2026-09-17 · View filing →

SEC FORM 4
$89,166.28

Travere Therapeutics, Inc. (TVTX)

Sale of 1,400 shares at $63.6902 per share.

Reporting Person REED ELIZABETH E · Officer Title Chief Legal Officer and GC · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001283303-26-000010 · filed 2026-09-17 · View filing →

SEC FORM 4
$19,593.00

Travere Therapeutics, Inc. (TVTX)

Sale of 300 shares at $65.31 per share.

Reporting Person REED ELIZABETH E · Officer Title Chief Legal Officer and GC · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001283303-26-000010 · filed 2026-09-17 · View filing →

SEC FORM 4
$984,750.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 39,000 shares at $25.25 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$712,114.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 39,650 shares at $17.96 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$3,961,850.56

Travere Therapeutics, Inc. (TVTX)

Sale of 63,907 shares at $61.994 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,818,316.56

Travere Therapeutics, Inc. (TVTX)

Sale of 29,021 shares at $62.6552 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$190,952.40

Travere Therapeutics, Inc. (TVTX)

Sale of 3,000 shares at $63.6508 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$17,633.70

Travere Therapeutics, Inc. (TVTX)

Sale of 270 shares at $65.31 per share.

Reporting Person ROTE WILLIAM E. · Officer Title Chief Research Officer · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001698262-26-000005 · filed 2026-09-17 · View filing →

SEC FORM 4
$2,232,844.44

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 95,666 shares at $23.34 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$3,936,526.76

Travere Therapeutics, Inc. (TVTX)

Sale of 63,498 shares at $61.9945 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,804,222.02

Travere Therapeutics, Inc. (TVTX)

Sale of 28,796 shares at $62.6553 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$197,421.83

Travere Therapeutics, Inc. (TVTX)

Sale of 3,102 shares at $63.6434 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$17,633.70

Travere Therapeutics, Inc. (TVTX)

Sale of 270 shares at $65.31 per share.

Reporting Person Dube Eric M · Officer Title CHIEF EXECUTIVE OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001763494-26-000007 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,055,927.04

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 39,283 shares at $26.88 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$30,934.40

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 1,381 shares at $22.40 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$326,177.18

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 36,526 shares at $8.93 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$4,463,875.19

Travere Therapeutics, Inc. (TVTX)

Sale of 71,938 shares at $62.0517 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,716,379.11

Travere Therapeutics, Inc. (TVTX)

Sale of 27,421 shares at $62.5936 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$89,112.94

Travere Therapeutics, Inc. (TVTX)

Sale of 1,400 shares at $63.6521 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$93,457.61

Travere Therapeutics, Inc. (TVTX)

Sale of 1,431 shares at $65.3093 per share.

Reporting Person Heerma Peter · Officer Title EVP, CHIEF COMMERCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001789617-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$68,750.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 2,500 shares at $27.50 per share.

Reporting Person Calvin Sandra · Officer Title SVP, CHIEF ACCOUNTING OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001882909-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$28,000.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 1,250 shares at $22.4 per share.

Reporting Person Calvin Sandra · Officer Title SVP, CHIEF ACCOUNTING OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001882909-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$33,247.50

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 1,625 shares at $20.46 per share.

Reporting Person Calvin Sandra · Officer Title SVP, CHIEF ACCOUNTING OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001882909-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$265,627.13

Travere Therapeutics, Inc. (TVTX)

Sale of 4,275 shares at $62.135 per share.

Reporting Person Calvin Sandra · Officer Title SVP, CHIEF ACCOUNTING OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001882909-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$50,278.48

Travere Therapeutics, Inc. (TVTX)

Sale of 800 shares at $62.8481 per share.

Reporting Person Calvin Sandra · Officer Title SVP, CHIEF ACCOUNTING OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001882909-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$19,098.99

Travere Therapeutics, Inc. (TVTX)

Sale of 300 shares at $63.6633 per share.

Reporting Person Calvin Sandra · Officer Title SVP, CHIEF ACCOUNTING OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001882909-26-000004 · filed 2026-09-17 · View filing →

SEC FORM 4
$289,287.35

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 32,395 shares at $8.93 per share.

Reporting Person Inrig Jula · Officer Title EVP, Head of R&D & CMO · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001902368-26-000008 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,574,604.01

Travere Therapeutics, Inc. (TVTX)

Sale of 25,390 shares at $62.0167 per share.

Reporting Person Inrig Jula · Officer Title EVP, Head of R&D & CMO · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001902368-26-000008 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,082,396.67

Travere Therapeutics, Inc. (TVTX)

Sale of 17,284 shares at $62.6242 per share.

Reporting Person Inrig Jula · Officer Title EVP, Head of R&D & CMO · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001902368-26-000008 · filed 2026-09-17 · View filing →

SEC FORM 4
$101,896.00

Travere Therapeutics, Inc. (TVTX)

Sale of 1,600 shares at $63.6850 per share.

Reporting Person Inrig Jula · Officer Title EVP, Head of R&D & CMO · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001902368-26-000008 · filed 2026-09-17 · View filing →

SEC FORM 4
$26,124.00

Travere Therapeutics, Inc. (TVTX)

Sale of 400 shares at $65.31 per share.

Reporting Person Inrig Jula · Officer Title EVP, Head of R&D & CMO · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001902368-26-000008 · filed 2026-09-17 · View filing →

SEC FORM 4
$348,800.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 20,000 shares at $17.44 per share.

Reporting Person Cline Christopher R. · Officer Title CHIEF FINANCIAL OFFICER · Transaction Code M

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001943192-26-000006 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,703,240.83

Travere Therapeutics, Inc. (TVTX)

Sale of 27,473 shares at $61.9969 per share.

Reporting Person Cline Christopher R. · Officer Title CHIEF FINANCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001943192-26-000006 · filed 2026-09-17 · View filing →

SEC FORM 4
$1,298,174.81

Travere Therapeutics, Inc. (TVTX)

Sale of 20,735 shares at $62.6079 per share.

Reporting Person Cline Christopher R. · Officer Title CHIEF FINANCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001943192-26-000006 · filed 2026-09-17 · View filing →

SEC FORM 4
$121,004.35

Travere Therapeutics, Inc. (TVTX)

Sale of 1,900 shares at $63.6865 per share.

Reporting Person Cline Christopher R. · Officer Title CHIEF FINANCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001943192-26-000006 · filed 2026-09-17 · View filing →

SEC FORM 4
$26,124.00

Travere Therapeutics, Inc. (TVTX)

Sale of 400 shares at $65.31 per share.

Reporting Person Cline Christopher R. · Officer Title CHIEF FINANCIAL OFFICER · Transaction Code S

Traded Sep 15, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001943192-26-000006 · filed 2026-09-17 · View filing →

SEC FORM 4
$174,400.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 10,000 shares at $17.44 per share.

Reporting Person Meckler Jeffrey A · Transaction Code M

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001506916-26-000004 · filed 2026-09-11 · View filing →

SEC FORM 4
$265,200.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 10,000 shares at $26.52 per share.

Reporting Person Meckler Jeffrey A · Transaction Code M

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001506916-26-000004 · filed 2026-09-11 · View filing →

SEC FORM 4
$111,165.89

Travere Therapeutics, Inc. (TVTX)

Sale of 1,700 shares at $65.3917 per share.

Reporting Person Meckler Jeffrey A · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001506916-26-000004 · filed 2026-09-11 · View filing →

SEC FORM 4
$79,380.00

Travere Therapeutics, Inc. (TVTX)

Sale of 1,200 shares at $66.15 per share.

Reporting Person Meckler Jeffrey A · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001506916-26-000004 · filed 2026-09-11 · View filing →

SEC FORM 4
$944,487.60

Travere Therapeutics, Inc. (TVTX)

Sale of 14,000 shares at $67.4634 per share.

Reporting Person Meckler Jeffrey A · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001506916-26-000004 · filed 2026-09-11 · View filing →

SEC FORM 4
$211,072.80

Travere Therapeutics, Inc. (TVTX)

Sale of 3,100 shares at $68.088 per share.

Reporting Person Meckler Jeffrey A · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001506916-26-000004 · filed 2026-09-11 · View filing →

SEC FORM 4
$42,609.54

Travere Therapeutics, Inc. (TVTX)

Sale of 642 shares at $66.37 per share.

Reporting Person Cline Christopher R. · Officer Title CHIEF FINANCIAL OFFICER · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001943192-26-000005 · filed 2026-09-03 · View filing →

SEC FORM 4
$87,200.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 5,000 shares at $17.44 per share.

Reporting Person LYONS GARY A · Transaction Code M

Traded Aug 18, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001123343-26-000010 · filed 2026-08-19 · View filing →

SEC FORM 4
$259,390.19

Travere Therapeutics, Inc. (TVTX)

Sale of 4,100 shares at $63.2659 per share.

Reporting Person LYONS GARY A · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001123343-26-000010 · filed 2026-08-19 · View filing →

SEC FORM 4
$57,470.13

Travere Therapeutics, Inc. (TVTX)

Sale of 900 shares at $63.8557 per share.

Reporting Person LYONS GARY A · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001123343-26-000010 · filed 2026-08-19 · View filing →

SEC FORM 4
$87,200.00

Travere Therapeutics, Inc. (TVTX)

Acquisition (code M) of 5,000 shares at $17.44 per share.

Reporting Person LYONS GARY A · Transaction Code M

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001123343-26-000010 · filed 2026-08-19 · View filing →

SEC FORM 4
$118,804.91

Travere Therapeutics, Inc. (TVTX)

Sale of 1,900 shares at $62.5289 per share.

Reporting Person LYONS GARY A · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001123343-26-000010 · filed 2026-08-19 · View filing →

SEC FORM 4
$165,099.74

Travere Therapeutics, Inc. (TVTX)

Sale of 2,600 shares at $63.4999 per share.

Reporting Person LYONS GARY A · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001123343-26-000010 · filed 2026-08-19 · View filing →

SEC FORM 4
$32,081.00

Travere Therapeutics, Inc. (TVTX)

Sale of 500 shares at $64.1620 per share.

Reporting Person LYONS GARY A · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001123343-26-000010 · filed 2026-08-19 · View filing →